anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
IDH1 mutations are thought to be among the earliest mutations occurring during transformation of glial cells into gliomas and dependence on the IDH-2HG pathway for survival and growth may be most relevant during the indolent phase of low grade tumor growth. However, the preclinical workup of IDH inhibitors was technically unable to assess low grade gliomas because the cells do not grow in vitro and so cannot be cultured, and the cells have such a low proliferation rate that they do not grow in mouse in vivo models. Despite this, Dr. Maher and colleagues have studied low grade metabolism in low grade gliomas in vivo, in patients undergoing surgical resection and infused with 13C-glucose or 13C-acetate. 13C-labeled tumor can be studied by 13C-nuclear magnetic resonance (NMR) ex vivo. 13C-NMR data from IDH-mutated low grade gliomas demonstrate that these tumors are highly metabolically active, capable of oxidizing both glucose and acetate while these substrates also contribute carbon to actively making 2HG (manuscript in preparation). These data strongly suggest that the low grade tumors may be dependent on the IDH pathway for maintaining the altered metabolic state of the cell and altered epigenome necessary for tumor growth. Treating low grade gliomas during the period of indolent growth poses a challenge in terms of evaluating a molecular targeted therapy for response and survival. Standard MRI assessment for low grade gliomas based on T2/FLAIR signal can be difficult to quantitate and reflects additional non-specific changes in the tumor microenvironment including edema and reactive gliosis. This is exacerbated by the natural history of these tumors for which there may be no change in tumor size over years. Added to this is the uncertainty that a drug was able to penetrate the blood brain barrier, enter the tumor and inhibit the target. To date, there is no non-invasive way to determine target inhibition, leaving the patients on a drug that may not inhibit the target and the investigator unsure if data being obtained reflects true activity. The current clinical trial addresses these challenges through a neoadjuvant clinical trial that combines non-invasive evaluation of 2HG by MRS to assess target inhibition within 1 week of study entry and direct tumor tissue analysis after 6 weeks on study in the surgical cohort. The comprehensive planned tissue analysis is designed to assess the impact of IDH305 on metabolic pathways, the epigenome and transcriptome, in addition to standard assessment of cellular proliferation and cell kill. A second cohort of patients, the non-surgical cohort, will include patients with a presumptive diagnosis of IDH-mutated glioma based on elevated 2HG on screening 2HG MRS but without a surgical resection planned because of perceived high risk of the procedure. It is anticipated that \~ 93% of these patients will have an IDH1 mutation and thus treatment with the IDH1 selective inhibitor will knockdown 2HG. For patients with an IDH2 mutation (\~7-8%), we anticipate that there will be no change in 2HG. These patients will come off study, sparing them any potential toxicity without potential benefit.
Every year, several millions of red cell concentrates are transfused. For each of them, a pretransfusional compatibility test is performed. In France, an ABO compatibility test at the patient's bedside is performed, but rhesus compatibility is not yet checked. However, rhesus antigens are very immunogenic and could lead to Rh incompatibility or Rh disease. Rh incompatibility occurs when a woman with Rh-negative blood type is exposed to Rh-positive blood cells. This exposure leads to the sensitization of the women who develop anti-Rh immunoglobulin G (IgG). This immunization is one cause of the hemolytic disease of newborns (HDN). HDN results from an incompatibility between mother's blood and fetus' blood. It happens when fetal red blood cells (RBCs) present antigens inherited from the father but missing from the mother. Consequence of this incompatibility is the fetal RBCs destruction by mother's antibodies. Antibodies could be natural, like immunoglobulin M (IgM) anti-A or anti-B from the ABO system, or from an immunization. Rh incompatibility results from 2 main mechanisms. The first one is when a pregnancy Rh-negative woman is exposed to fetal Rh-positive RBCs. Rh incompatibility leads to anemia (mild to severe) or ultimately to the in utero death. The second occurs when Rh incompatible blood is transfused. This is the subject of this communication.

The investigators previously develop biochips and optical device to realize automatic ABO compatibility test at the patient's bedside (references to the Citation field). Based on this previously project, the goal of ABORDAGE project is to develop another biochip based on selective blood capture. The ABORDAGE chip has to specifically capture RBCs according the presence of the RH1 antigen (also known as D antigen) at their surface.
Patients undergo nerve-sparing radical prostatectomy per standard of care. Patients then receive sham LiSWT treatment weekly for 6 weeks, then have a 6 week break, followed by 6 more weekly treatments. Patients also undergo DDUS at baseline and during follow up.
Provided are a medical-image retrieval method, device, and computer program which are capable of using newly X-rayed images to retrieve with a high degree of accuracy pre-existing images which correspond to similar medical cases. Images similar to a newly imaged image are retrieved from among medical images based on past medical cases. Wavelet features of a plurality of previously imaged and stored images are calculated, and keywords included in radiographic image interpretation information for each stored image are extracted. The newly imaged image is acquired, wavelet features of the acquired image are calculated, and keywords included in the radiographic image interpretation information corresponding to the acquired image are extracted. Similar radiographic image interpretation information is retrieved from stored keywords on the basis of the extracted keywords, and the wavelet-feature based spatial distance between images corresponding to the retrieved radiographic image interpretation information and the acquired image is calculated. Images having a calculated spatial distance that is shorter than a prescribed value are outputted as retrieval results in order of the shortest spatial distance.
Human mesenchymal stem cells (MSCs), derived from healthy adult volunteer human donors, can be obtained from bone marrow donation and cultured in the laboratory. MSCs have shown the ability to find injured tissue, reduce and control inflammation, and assist in tissue repair.

Prochymal™ MSCs will be infused into patients with moderate-to-severe Crohn's disease. Infusions will occur on two separate days, 7-10 days apart. Patients will be monitored for reduced Crohn's disease symptoms. Patients will receive high or low dose. Study is open label.
The patients were instructed to stand with straight legs on a small step, lift up on the toes, hereafter put the weight on the injured leg and slowly lower the heel as far as possible until they felt a maximal stretch of the calf muscles and/or the Achilles tendon. The exercises were repeated 15 times. Then the patients were told to repeat the exercises with semi-flexed knee. If possible the series should be repeated twice increasing to three times at each session. If pain decreased they should increase the load on the Achilles tendons by wearing a rug sack and increasing the weight of the rug sack by adding weights (5kg each). The patients were told that some pain was to be expected from the tendon during exercise, but that increasing daily pain or morning stiffness indicated that the exercises had been progressed too fast.
There is disclosed a composition or kit for use in so-called viscodye enhanced ocular surgery, i.e. cataract surgery. The composition comprises a first viscoelastic substance containing a visualising agent (viscodye) used for staining the capsule of the crystalline lens prior to a Continious Curvilinear Capsulorhexis (CCC). A kit contains in addition a second clear viscoelastic agent for protection and expansion. The viscosity of the viscodye secures safe and precise application within the eye and the visualising agent can be used in such low concentrations, that the surgeon is allowed to see and work through it.The viscoelastic substance preferably comprises at least one of methylene hydroxypropylene cellulose, sodium hyaluronate, and sodium chondroitinsulfatesodium hyaluronate. The visualizing agent may be chosen from e.g. azophlozin, basic blue, Bismarck brown, basis red, Bengal red, brilliant cresyl blue,eosin, fluorescein, gentian violet, indocyanine green, Janus green, methylene green, methylene blue, neutral red and trypan blue.
PURPOSE:To provide a sugar transfusion solution exhibiting excellent nutrient- supplying effect by intravenous injection, and useful as a remedying transfusion solution for the patient of diabetes, etc. having lowered resistance to sugar, by adding palatinose to an aqueous solution. CONSTITUTION:The objective sugar transfusion solution contains palatinose in an aqueous solution. The preferable concentration ranges of sugars and the electrolyte elements in the aqueous solution are shown in Table 1. The transfusion solution is preferably filled in a plastic container to prevent the formation of flakes. Since the direct intravenous injection of glucose is avoided in the above transfusion solution, the rapid increase in the blood sugar level can be inhibited, and the transfusion can be applied to the patient of diabetes or postoperative diabetes having lowered resistance to sugar. The palatinose can be prepared by converting sucrose with an enzyme existing in a specific bacterium.
Patients with type 2 diabetes using insulin pump therapy are gaining weight within the first months of treatment. This weight gain could counterbalance the metabolic benefice of insulin pump treatment in improving glycemic control and could lead to treatment dropout. Lifestyle intervention aiming at improving physical activity and diet in type 2 diabetes is known to brought body weight reduction and cardiometabolic improvement.

The investigator hypothesized that an intensive, home-based, 6-months diet and physical activity program could prevent the body weight gain associated with insulin pump treatment initiation. The investigator will randomize patients with type 2 diabetes into a "lifestyle intervention" arm or a "usual care" control arm at the time of insulin pump treatment initiation. The primary objective will evaluate body weight change at 6 months after insulin pump treatment initiation. The secondary objectives will evaluate change in glycemic control (HbA1c) and body composition at 6 months. In addition, the retention effect will be assessed on body weight change one year after insulin pump treatment initiation, 6 months after the end of the lifestyle intervention.
INTRODUCTION: Quick and simple parameters are needed to predict mortality in patients with idiopathic pulmonary fibrosis (IPF). In this way, risky patients will have the opportunity to receive early and effective treatment. In this study, we examined whether the Fibrosis-4 index (FIB-4) and systemic immune inflammation index (SII) are associated with mortality in IPF patients.
MATERIALS AND METHODS: The study was designed retrospectively. 100 patients diagnosed with IPF were included in the study. Variables between living patients and deceased patients were examined.
RESULTS: Out of a total of 100 patients, 67 were divided into the surviving group and 33 into the non-surviving group. In multivariate analysis, high FIB-4 and SII values were significantly associated with an increased risk of death.
CONCLUSION: FIB-4 and SII are parameters that can predict mortality in IPF patients. In this way, IPF patients with high mortality risk will be identified earlier and more effective methods will be used in follow-up and treatment.
PURPOSE: To provide a pharmaceutical compsn. which is suitable for topical application in the treatment of dermatoses by comprising as an active ingredient an o-ester of L-carnitine.  
     CONSTITUTION: This pharmaceutical compsn. is topically applied in the treatment of dermatoses and contains as an active ingredient an o-ester of L-carnitine represented by formula (wherein R represents acyl selected from the group consisting of satd. dicarboxylic acids or urisatd. monocarboxylic acids; and X -  represents an anion of a pharmacologically acceptable acid). In the formula, the satd. dicarboxylic acid may be selected from among azelain, sebacic acid, suberic acid, and pimelic acid. The unsatd. monocarboxylic acid may be selected from among linoleic acid, linolenic acid, oleic acid, and arachidonic acid. Dermatoses suitable in the treatment using this compsn. include particularly ichthyosis, psoriasis, and dermatoses derived from keratogenesis diseases, such as dander, acne, and hyperkeratosis of palm or planta. Pref., the compd. of formula is incorporated in an amt. of 0.01 to 20 wt.%, particularly pref. 2 to 10 wt.%. 
     COPYRIGHT: (C)1995,JPO
PET-MR scan session with purely consummatory food reward (drinking sips of chocolate milkshake). This scan session will consist of four blocks with a duration of 45 minutes each and 15 minute breaks in between. The first three blocks represent the 'control condition' (drinking sips of water) and the fourth block the 'food reward condition' (drinking sips of chocolate milkshake).
PURPOSE: A pharmaceutical formulation is provided to include a growth hormone, an amino acid being selected from the group of Asp, Ile, Val, Leu, or His and a polysorbate or a poloxamer. CONSTITUTION: The invention relates to pharmaceutical formulations comprising growth hormone, an amino acid selected from the group of Asp, Ile, Val, Leu or His, or a derivative of histidine, or a peptide comprising at least one basic amino acid and at least one acidic amino acid, and a non-ionic detergent, e.g. polysorbate or poloxamer. The formulation is stabilized against deamidation and aggregation. The formulation may be an aqueous formulation. The growth hormone may be human growth hormone.
Subjects will be identified following admission to hospital who test positive for COVID-19 infection. They will then be informed and consented, and eligibility confirmed and registered to study. Following this the first, sentinel patient, will be treated with 0.5Gy dose radiotherapy to cover the lungs, with heterogeneity correction. A further 0.5Gy dose can be repeated within 96 hours. There shall then be a 7 day gap prior to recruiting patient 2. The remaining patients will be recruited, treated and observed in cohorts of 3.

The patients shall then be followed up at 48 hours post Radiotherapy, 7 days post radiotherapy and 29 days post radiotherapy. With assessment of Physiological parameters, survival status, laboratory testing and imaging performed on follow up at 7 and 29 days.
For 30 minutes, exercises including trunk, lower extremity and upper extremity exercises specific to the individual will be practiced, while the movement patterns to be used in the robotic system will be practiced in the other 30 minutes with the physiotherapist. Individual-specific rehabilitation program; individual-specific trunk, lower extremity and upper extremity exercises to be applied in both groups will consist of the following exercises according to the needs of the patients, and the degree of difficulty will be planned according to the needs of the patients. All patients will be treated for 8 weeks, 3 days a week, 60 minutes a day.
Because of the wide variation in the absorption and distribution of tricyclic antidepressants in body fluids, it is difficult to directly correlate plasma levels and therapeutic effect. However, determination of plasma levels may be useful in identifying patients who appear to have toxic effects and may have excessively high levels, or those in whom lack of absorption or noncompliance is suspected. Because of increased intestinal transit time and decreased hepatic metabolism in elderly patients, plasma levels are generally higher for a given oral dose of amitriptyline hydrochloride than in younger patients. Elderly patients should be monitored carefully and quantitative serum levels obtained as clinically appropriate. Adjustments in dosage should be made according to the patient's clinical response and not on the basis of plasma levels.2

* * *

2
    Hollister, L.E.; Monitoring Tricyclic Antidepressant Plasma Concentrations. JAMA 1979; 241(23):2530-2533.
PURPOSE:To effectively effect hemostasis at the time of removing an injection needle punctured into a blood vessel, catheter, tube for medical treatment, etc., in blood taking, instillation blood transfusion, artificial dialysis, etc. CONSTITUTION:A tacky adhesive layer 2 is provided on one surface of a base material 1 and a pad 3 is fixed onto the tacky adhesive layer. The pad 3 has such a size at which both of the puncture hole of the blood vessel and the puncture hole of the skin surface can be covered when the injection needle or the like is punctured into the blood vessel. The pad 3 has such a thickness and compressive hardness at which both puncture holes can be pressed with suitable strength. As result, the pad 3 is pressed to the puncture part at the time of removing the injection needle, etc., and is stuck to the place after the needle is removed. The thick and slightly hard pad is pressed to the puncture hole of the blood vessel, by which the puncture hole is concentrically compressed and the hemostasis is effected. The puncture hole of the skin surface is simultaneously covered with the pad to make the bleeding from the hole absorbed. The hemostasis in the case of use of the large-sized injection needle, etc., is assured as well.
The invention relates to a compound panax-notoginseng tablet. The tablet is a medicine for treating traumatic injury, arthralgia and myalgia, early and latest stasis wound and rheumatic numbness, concretely is a Chinese patent medicine prepared by taking Chinese herbal medicines as raw materials, and is capable of treating various blood stasis and oedema caused by traumatic injury, fracture and soft tissue damage. The invention also relates to a preparation method of the medicine. The table is an oral tablet prepared by taking panax notoginseng, ground beetle, flos carthami, radix angelicae sinensis, rhizoma Chuanxiong, herba taxilli, radix angelicae dahuricae as bulk drugs and performing screening, drying and crushing on the raw materials through a provided tablet preparation technology. The provided formula is definite in therapeutic effect, and the tablet is an ideal medicine capable of rapidly treating various blood stasis and oedema caused by traumatic injury, fracture and soft tissue damage. The invention also relates to a preparation method of the medicine. The tablet is simple in preparation method, easy to process and easy for large-scale production.
At present, clinical practice and research in movement disorders (MDs) focus on the "normalization" of altered movements. In this review, rather than concentrating on problems and burdens people with MDs undoubtedly have, we highlight their hidden potentials. Starting with current definitions of Parkinson's disease (PD), dystonia, chorea, and tics, we outline that solely conceiving these phenomena as signs of dysfunction falls short of their complex nature comprising both problems and potentials. Such potentials can be traced and understood in light of well-established cognitive neuroscience frameworks, particularly ideomotor principles, and their influential modern derivatives. Using these frameworks, the wealth of data on altered perception-action integration in the different MDs can be explained and systematized using the mechanism-oriented concept of perception-action binding. According to this concept, MDs can be understood as phenomena requiring and fostering flexible modifications of perception-action associations. Consequently, although conceived as being caught in a (trough) state of deficits, given their high flexibility, people with MDs also have high potential to switch to (adaptive) peak activity that can be conceptualized as hidden potentials. Currently, clinical practice and research in MDs are concerned with deficits and thus the "deep and wide troughs," whereas "scattered narrow peaks" reflecting hidden potentials are neglected. To better delineate and utilize the latter to alleviate the burden of affected people, and destigmatize their conditions, we suggest some measures, including computational modeling combined with neurophysiological methods and tailored treatment. © 2024 International Parkinson and Movement Disorder Society.
INTRODUCTION: Although observational data suggest a relationship between headache and smoking, there remain questions about causality. Smoking may increase headache risk, individuals may smoke to alleviate headaches, or smoking and headache may share common risk factors. Mendelian randomization (MR) is a method that uses genetic variants as instruments for making causal inferences about an exposure and an outcome.
AIMS AND METHODS: First, we conducted logistic regression of observational data in UK Biobank assessing the association between smoking behaviors (smoking status, cigarettes per day amongst daily smokers, and lifetime smoking score) on the risk of self-reported headache (in the last month and for more than 3 months). Second, we used genetic instruments for smoking behaviors and headache (identified in independent genome-wide association studies [GWAS]) to perform bidirectional MR analysis.
RESULTS: Observationally, there is a weak association between smoking behavior and experiencing headache, with increased cigarettes per day associated with increased headache risk. In the MR analysis, genetic liability to smoking initiation and lifetime smoking increased odds of headache in the last month but not odds of headaches lasting more than 3 months. In the opposite direction, there was weak evidence for higher genetic liability to headaches decreasing the chance of quitting.
CONCLUSIONS: There was weak evidence for a partially bidirectional causal relationship between smoking behaviors and headache in the last month. Given this relationship is distinct from smoking heaviness, it suggests headache and smoking may share common risk factors such as personality traits.
IMPLICATIONS: Using MR, this study addresses the uncertainty regarding the observed relationship between headache and smoking. There was evidence for weak causal effects of smoking initiation and lifetime smoking (but not smoking heaviness) on likelihood of experiencing headache in the last month, but not over a prolonged period of more than 3 months. Those with higher genetic liability to headaches were also less likely to successfully stop smoking. This partially bidirectional causal relationship distinct from smoking heaviness suggests that observed associations are unlikely due to biological effects of tobacco smoke exposure and may be explained by shared personality traits.
Some patients with COVID-19 develop symptoms after the acute infection, known as 'Long COVID'. We examined whether or not confirmation of COVID-19 infection status could act as a nocebo, using data from questionnaires distributed to the Avon Longitudinal Study of Parents and Children cohort. We examined associations between confirmation of COVID-19 infection status (confirmed by a positive test vs unconfirmed) and reporting of Long COVID symptoms. We explored the roles of sex and anxiety as potential moderators. There was no clear evidence of a strong association between confirmation of COVID-19 infection status and the Long COVID composite score, physical or psychological symptoms or duration of symptoms. There was no clear evidence of moderation by sex or anxiety. We therefore found no evidence of a nocebo effect. Our data suggest that this psychological mechanism does not play a role in the medical symptomatology experienced by patients with Long COVID.